Viking reports positive Phase 2b NASH data, $393M cash; net loss $19.2M

Viking Therapeutics, Inc.

2023-Q2 EPS reported -$0.44

VK2809 Phase 2b VOYAGE hit primary endpoint: median liver fat reduction 38-55%; up to 85% of patients achieved ≥30% reduction.
VK2809 showed significant reductions in LDL-C and triglycerides; Phase 2b 52-week biopsy results expected 1H24.
Phase 2 study of obesity candidate VK2735 to start 3Q23; Phase 1 oral formulation data expected 4Q23.
Net loss $19.2M ($0.19 loss/share) vs $17.4M ($0.23) in Q2 2022; R&D spend $13.9M, G&A $9.8M.
Ended Q2 with $393M cash, boosted by $288M stock offering; cash runway through multiple catalysts.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Viking Therapeutics, Inc. reported financial results for second quarter and six months ended June 30, 2023.

Period: second quarter and six months ended June 30, 2023
Result: reported results

Exact text from the filing

On July 26, 2023, we issued a press release reporting our financial results for the second quarter and six months ended June 30, 2023 and providing a corporate update.

View on SEC.gov

Browse all earnings releases →

Viking Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-034741

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.